Literature DB >> 3737015

Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.

T L Perry, V W Yong.   

Abstract

Glutathione transferase activity and total glutathione (GSH) content were measured in several regions of autopsied brain from patients dying with idiopathic Parkinson's disease (PD) or progressive supranuclear palsy (PSP), and from control subjects. A significant deficiency of GSH was found in the substantia nigra, but not in 5 other brain regions of PD patients, nor in PSP patients' brains. Glutathione transferase activity was similar in the substantia nigra of PD, PSP and control patients. Since total GSH is consumed only by conjugation in detoxification processes, nigral GSH deficiency in PD patients implies continued local presence of a possible causative neurotoxin up to the time of death.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3737015     DOI: 10.1016/0304-3940(86)90320-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  76 in total

1.  Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease.

Authors:  Shankar J Chinta; Jyothi M Kumar; Hongqiao Zhang; Henry Jay Forman; Julie K Andersen
Journal:  Free Radic Biol Med       Date:  2006-01-13       Impact factor: 7.376

2.  Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration.

Authors:  Erik S Musiek; Rebecca S Breeding; Ginger L Milne; Giuseppe Zanoni; Jason D Morrow; Bethann McLaughlin
Journal:  J Neurochem       Date:  2006-04-21       Impact factor: 5.372

Review 3.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

4.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 5.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 6.  Transplantation into the human brain: present status and future possibilities.

Authors:  O Lindvall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 7.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

8.  Modulation of [3H]dopamine release by glutathione in mouse striatal slices.

Authors:  Réka Janáky; Róbert Dohovics; Pirjo Saransaari; Simo S Oja
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

9.  A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease.

Authors:  Donna W Lee; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Julie K Andersen
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

Review 10.  Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

Authors:  P Jenner
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.